Panbela Therapeutics Inc.

Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing disruptive treatments for patients facing urgent unmet medical needs, particularly in oncology. The company’s principal focus lies in advancing therapeutic candidates for pancreatic and other gastrointestinal cancers. Its leading product, Ivospemin (SBP-101), a proprietary polyamine analogue, has completed Phase Ia/Ib clinical trials targeting metastatic pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer. Another key asset, Flynpovi—a combination of eflornithine (CPP-1X) and sulindac—is in Phase III trials, aimed at cancer prevention and treatment. Panbela also pursues Eflornithine, an irreversible inhibitor of ornithine decarboxylase, under investigation in early-phase trials. The company’s research collaborations, including agreements with academic institutions such as Johns Hopkins University School of Medicine, bolster its pipeline development. Founded in 2011 and based in Minnesota, Panbela Therapeutics operates with the mission to address significant gaps in treatment options within the oncology landscape, positioning itself as a contributor to advancements in cancer therapeutics.